DMF (Dimethyl Fumarate) †Rx

DMF activates NRF2 (antioxidant induction) but overloads tumor ROS; inhibits NF-κB/PI3K for apoptosis. Preclinical strong in GBM/breast/CRC; no oncology trials yet—monitor lymphopenia/flushing.

← All agents

Human-reviewed · How we review →

AI extractedhuman reviewedsources checkedretractions suppressed

🔬⭐⭐ Preclinical — Robust mechanistic/animal data; no human oncology trials yet.Dimethyl FumarateTecfideraBG-12

Forms: Oral delayed-release capsules (Rx, 120–240 mg)

Educational only, not medical advice. OncoForge makes no claim that DMF (Dimethyl Fumarate) †Rx treats, prevents, or cures any condition, beyond what the linked studies show. Evidence levels vary; effects may not translate to people, and some compounds can cause harm. Always coordinate with your oncology team.

Simple Summary

MS drug that turns on the NRF2 defense program while paradoxically pushing over-stressed cancer cells into ROS-driven death. Strong lab support; clinical cancer trials are not yet established.

Evidence at a glance

Tier 2 · animalGlioblastomaBreastColorectal

Preclinical mechanistic/animal robust; human oncology absent (MS data translates safety).

How it may work

DMF alkylates Keap1 to activate NRF2, inducing antioxidant/phase-II enzymes (HO-1, NQO1). Tumor cells, already redox-stressed, can tip into lethal ROS with DMF. DMF also inhibits NF-κB and downshifts PI3K/AKT, promoting apoptosis in multiple preclinical models.

Targets & pathways

Curated mechanistic targets reported for this agent — how it may act on cells, not proof of a clinical effect.

NRF2↑Via Keap1 alkylation; induces HO-1, NQO1
ROS↑In redox-stressed tumor cells; selective lethality
NF-κB↓Inhibits translocation; reduces inflammation
Apoptosis↑Via PI3K/AKT downshift; Bcl-2 ↓
PI3K/AKT↓Suppresses survival signaling

NRF2ROSNF-κB

Often studied / combined with

Combinations reported in the literature, not a protocol or a recommendation.

Temozolomide: Apoptosis enhancement in GBM.
Radiotherapy: Tumor sensitivity boost in breast.
Curcumin: ROS/apoptosis in GBM.
Resveratrol: NRF2/ROS in CRC.
EGCG: NF-κB/apoptosis in breast.
Quercetin: ROS/PI3K in GBM.

Overlapping mechanisms

NRF2 ↑ / ROS ↑: Caution stacking with other NRF2 activators; may desensitize tumors or amplify normal cell protection.

Safety & interactions

Severity and how well-established each signal is are shown separately. Verify everything with your oncologist or pharmacist — absence here does not mean safe.

Risk categories

Lymphopenia RiskHepatotoxicity Risk MildGi Upset ModerateInfection RiskPregnancy Avoid

Potential interactions

Aspirin/NSAIDsConsiderBeneficialTheoreticalPre-dose aspirin mitigates flushing.
Redox agents (e.g., high-dose antioxidants)MonitorModerateTheoreticalMay blunt selective ROS effect in tumors.
Temozolomide / RadiotherapyConsiderBeneficialTheoreticalSynergistic apoptosis/ROS in GBM/breast.
Curcumin / Resveratrol / EGCG / QuercetinConsiderBeneficialTheoreticalEnhances ROS/apoptosis/NF-κB/PI3K inhibition.

Timing

With food: Reduces GI upset.
BID dosing: Steady-state levels; titrate up over weeks.
30 min after aspirin (optional): For flushing prophylaxis.

References

Research

No published studies for DMF (Dimethyl Fumarate) †Rx yet

New studies appear here once they’ve been reviewed. Browse all studies.

Dose: as studied, not a recommendation

These are doses as studied or reported, never a recommendation. The right amount of DMF (Dimethyl Fumarate) †Rx depends on you, your other medicines, and your situation; decide it with your oncology team and pharmacist, not from a web page.

Ranges seen in adjunct / practice use: 120–480 mg (po) Standard MS regimen: 120 mg BID for 1 week, then 240 mg BID (total 480 mg/day). Investigational cancer use: similar starting doses (e.g., 240–360 mg/day) with escalation; no established oncology HED from animals as primarily human-derived data., Rx required. Aspirin 325 mg 30 min prior may reduce flushing. Titrate slowly to minimize GI/flushing. Pulsed or lower-dose schedules explored preclinically for cancer. Strict clinician oversight; monitor CBC/LFTs monthly..

Trials studying DMF (Dimethyl Fumarate) †Rx

No actively-recruiting trials matched right now. Recruiting is not the same as proven. Search ClinicalTrials.gov →

Inclusion here is not an endorsement. OncoForge makes no claim beyond what the linked studies show. Discuss anything on this page with your oncology team before acting on it.

← All agents · Research Radar